Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
The relationship between dopamine D-2 receptor polymorphism at the Taq1 A locus and therapeutic response to nemonapride, a selective dopamine antagonist, in schizophrenic patients
Autore:
Suzuki, A; Mihara, K; Kondo, T; Tanaka, O; Nagashima, U; Otani, K; Kaneko, S;
Indirizzi:
Hirosaki Univ, Sch Med, Dept Neuropsychiat, Hirosaki, Aomori 0368562, Japan Hirosaki Univ Hirosaki Aomori Japan 0368562 rosaki, Aomori 0368562, Japan Yamagata Univ, Sch Med, Dept Neuropsychiat, Yamagata 99023, Japan YamagataUniv Yamagata Japan 99023 Neuropsychiat, Yamagata 99023, Japan
Titolo Testata:
PHARMACOGENETICS
fascicolo: 4, volume: 10, anno: 2000,
pagine: 335 - 341
SICI:
0960-314X(200006)10:4<335:TRBDDR>2.0.ZU;2-C
Fonte:
ISI
Lingua:
ENG
Soggetto:
A1 ALLELE; GENE; BINDING; ASSOCIATION; CLOZAPINE; CLONING; ANTIPSYCHOTICS; STRIATUM; LEVEL; RFLP;
Keywords:
Taq1 A DRD2 polymorphism; nemonapride; therapeutic response; schizophrenia;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
37
Recensione:
Indirizzi per estratti:
Indirizzo: Kondo, T Hirosaki Univ, Sch Med, Dept Neuropsychiat, Hirosaki, Aomori 0368562, Japan Hirosaki Univ Hirosaki Aomori Japan 0368562 omori 0368562, Japan
Citazione:
A. Suzuki et al., "The relationship between dopamine D-2 receptor polymorphism at the Taq1 A locus and therapeutic response to nemonapride, a selective dopamine antagonist, in schizophrenic patients", PHARMACOGEN, 10(4), 2000, pp. 335-341

Abstract

Previous studies have demonstrated that subjects with one or two Al alleles of dopamine D-2 receptor (DRD2) polymorphism at the Taq1 A locus have lower DRD2 density than those with no A1 allele. The present study aimed to examine whether the Taq1 A DRD2 genotypes are related to therapeutic responseto nemonapride, a selective dopamine antagonist, in schizophrenic patients, The subjects were 25 acutely exacerbated schizophrenic inpatients who hadreceived no medication for at least 1 month before the study. The fixed dose (18 mg/day) of nemonapride was administered to each patient for 3 weeks,The clinical status was prospectively monitored by the Brief Psychiatric Rating Scale (BPRS) before, and 3 weeks after, the treatment. The Taq1 A genotypes (A1 and A2 alleles) were determined by the polymerase chain reactionmethod. Three patients were homozygous for the Al allele, 11 were heterozygous for the A1 and A2 alleles, and 11 were homozygous for the A2 allele. The patients with one or two A1 alleles (n = 14) showed significantly higherpercentage improvement in total BPRS and positive symptoms than those withno A1 allele (n = 11) after 3-week treatment while the percentage improvement in other subgrouped symptoms (negative, anxiety-depression, excitement and cognitive symptoms) was similar between the two genotype groups. The present results suggest that the Taq1 A DRD2 polymorphism is related to earlytherapeutic response to nemonapride in schizophrenic patients, possibly bymodifying the efficiency of DRD2 antagonism of the drug in the central nervous system. Pharmacogenetics 10:335-341 (C) 2000 Lippincott Williams & Wilkins.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 09/04/20 alle ore 13:29:12